跳至主要内容
临床试验/JPRN-UMIN000001243
JPRN-UMIN000001243已完成2 期

Phase II clinical trial of personalized peptide vaccination for standard therapy failure patients with malignant glioma (glioblastoma) - Personalized peptide vaccination for patients with glioblastoma

Department of Immunology, Kurume University School of medicine0 个研究点目标入组 40 人开始时间: 2008年7月11日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with multiple cancers 3) Patients with the past history of severe allergic reactions. 4) Patients who are not accept contraception during the 1st vaccination to 70 days after the last vaccination. 5) Patients with positive for hepatitis B or C virus. 6) Patients who are judged inappropriate for the clinical trial by doctors.

研究者

发起方
Department of Immunology, Kurume University School of medicine

相似试验

Phase II clinical trial of personalized peptide... | 临床试验